Literature DB >> 2653724

Cryotherapy for medically unresponsive acanthamoeba keratitis.

P S Binder1.   

Abstract

Five cases of culture-proven Acanthamoeba keratitis underwent cryotherapy to the host cornea as an adjunctive treatment to medical and surgical therapy. Four of the 5 cases had progression of disease while receiving medical therapy considered to be appropriate for Acanthamoeba keratitis. One case underwent cryotherapy to the entire cornea after the disease had recurred in two penetrating keratoplasties; the organisms were eliminated but the patient never recovered useful vision. Two cases underwent cryotherapy to the host cornea at the time of a second penetrating keratoplasty. The organism was eliminated in both cases. Two cases underwent cryotherapy to the host cornea at the time of primary corneal transplantation with elimination of the organism and recovery of excellent acuity. This study does not provide conclusive evidence that cryotherapy eliminated the organism, but suggests that it can be an adjunctive measure to medical and surgical therapy. The risks of the adverse effects of freezing of the cornea must be weighted against the possibility of recurrence after keratoplasty with spread of disease to the sclera or to the development of corneal melting and perforation. Prevention of Acanthamoeba keratitis is by far the best approach to this disease entity.

Entities:  

Mesh:

Year:  1989        PMID: 2653724

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  10 in total

1.  RNA interference-independent reprogramming of DNA methylation in Arabidopsis.

Authors:  Taiko Kim To; Yuichiro Nishizawa; Soichi Inagaki; Yoshiaki Tarutani; Sayaka Tominaga; Atsushi Toyoda; Asao Fujiyama; Frédéric Berger; Tetsuji Kakutani
Journal:  Nat Plants       Date:  2020-11-30       Impact factor: 15.793

2.  Crosslinking and corneal cryotherapy in acanthamoeba keratitis -- a histological study.

Authors:  Tobias Hager; A Hasenfus; T Stachon; B Seitz; N Szentmáry
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-01       Impact factor: 3.117

3.  In vitro amoebicidal activities of Teucrium polium and T. chamaedrys on Acanthamoeba castellanii trophozoites and cysts.

Authors:  Bektas Tepe; Erdogan Malatyali; Serpil Degerli; Seyda Berk
Journal:  Parasitol Res       Date:  2011-10-26       Impact factor: 2.289

4.  Excisional keratectomy combined with focal cryotherapy and amniotic membrane inlay for recalcitrant filamentary fungal keratitis: A retrospective comparative clinical data analysis.

Authors:  Yingxin Chen; Minghong Gao; Joshua K Duncan; Di Ran; Denise J Roe; Michael W Belin; Mingwu Wang
Journal:  Exp Ther Med       Date:  2016-09-13       Impact factor: 2.447

5.  Riboflavin and ultraviolet A as adjuvant treatment against Acanthamoeba cysts.

Authors:  Ricardo Lamy; Elliot Chan; Samuel D Good; Vicky Cevallos; Travis C Porco; Jay M Stewart
Journal:  Clin Exp Ophthalmol       Date:  2016-02-23       Impact factor: 4.207

6.  [Delayed course of Acanthamoeba keratitis].

Authors:  A G Schnaidt; Z Gatzioufas; F Schirra; A K Hasenfus; B Seitz
Journal:  Ophthalmologe       Date:  2013-02       Impact factor: 1.059

7.  In vitro evaluation of the amebicidal activity of Pterocaulon polystachyum (Asteraceae) against trophozoites of Acanthamoeba castellanii.

Authors:  Camila Ródio; Damiana da Rocha Vianna; Kreesla Passos Kowalski; Lua Ferreira Panatieri; Gilsane von Poser; Marilise Brittes Rott
Journal:  Parasitol Res       Date:  2008-09-16       Impact factor: 2.289

Review 8.  Acanthamoeba spp. as agents of disease in humans.

Authors:  Francine Marciano-Cabral; Guy Cabral
Journal:  Clin Microbiol Rev       Date:  2003-04       Impact factor: 26.132

9.  Acanthamoeba sclerokeratitis.

Authors:  Katayoon B Ebrahimi; W Richard Green; Rhonda Grebe; Albert S Jun
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-10-09       Impact factor: 3.117

10.  Acanthamoeba Keratitis: an update on amebicidal and cysticidal drug screening methodologies and potential treatment with azole drugs.

Authors:  Brian Shing; Mina Balen; James H McKerrow; Anjan Debnath
Journal:  Expert Rev Anti Infect Ther       Date:  2021-05-19       Impact factor: 5.091

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.